Seasonal influenza virus vaccine trivalent - sanofi pasteur

Drug Profile

Seasonal influenza virus vaccine trivalent - sanofi pasteur

Alternative Names: Fluzone; Fluzone Pediatric; Trivalent influenza virus vaccine seasonal - sanofi pasteur; Vaxigrip

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator sanofi pasteur
  • Developer Sanofi Pasteur
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 01 Aug 2015 Launched for Influenza virus infections (In children, In infants, In adults) in Malaysia, Italy, Indonesia, Hungary, France, Finland, Denmark, Austria, Australia, South Africa, Russia, Israel, Belgium, Spain, Netherlands, China, Chile, Turkey, Singapore, Portugal, Poland, Philippines, New Zealand, Greece (IM) before August 2015
  • 01 Jan 2009 Launched for Influenza virus infections in USA (IM)
  • 04 Sep 2002 Registered for Influenza virus infections (prevention in adults, children and infants) in USA (IM) - first global approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top